Norwegian Cancer Society   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Oslo Norway (1938)

Organization Overview

First Clinical Trial
2005
NCT00139360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Norwegian Cancer Society

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Hyperplasia (Phase 4)

Glioblastoma (Phase 1)

Head and Neck Neoplasms (Phase 1)

Hyperplasia (Phase 4)

Liver Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Follicular (Phase 2)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Prostatic Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 28